Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2023 First Quarterly Report
TheBoardof Directors andall DirectorsoftheCompanyherebywarrant that there
are no false representations, misleading statements or material omissions contained in
this announcement and accept legal responsibility for the truthfulness, accuracy and
completeness of the contents hereof.
IMPORTANT NOTICE:
The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this
quarterly report, and that there are no false representations, misleading statements or material
omissions contained herein, and severally and jointly accept legal responsibility.
The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant the
truthfulness,accuracyandcompletenessofthefinancialinformationcontainedinthisquarterlyreport.
Whether the first quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
Item The Reporting Period YoY change (%)
(From January to March)
Revenues 4,559,049,786.82 -2.11
Net profit attributable to shareholders 462,746,183.03 0.48
of the listed company
Net profit attributable to shareholders
of the listed company after deduction 446,772,473.94 -2.28
of extraordinary gains and losses
Net cash flow from operating activities 248,084,750.71 -71.55
Basic earnings per share (RMB/share) 0.2404 -0.31
Diluted earnings per share 0.2398 -0.48
(RMB/share)
Weighted average return on net assets 3.49 Decreased by 0.35 percentage points
(%)
Change as at the
end of the
As at the end of the As at the end of the Reporting Period
Reporting Period previous year as compared to
the end of the
previous year(%)
Total assets 36,193,051,015.06 35,729,253,651.41 1.30
Owner's equity attributable to 13,365,070,332.08 13,121,820,410.55 1.85
shareholders of the listed company
Notes: FromJanuaryto March 2023, the Companyrealized revenues ofRMB4,559 million, representinga YoY
decrease of 2.11%. Chemical pharmaceuticals realized revenues of RMB2,250 million, representing a YoY
decrease of 16.09%, among which, RMB509 million were from respiratory formulation products, representing
a YoY increase of 41.18%; RMB793 million were from gastroenterology products, representing a YoY
decrease of 25.23%; RMB577 million were from gonadotropic hormones, representing a YoY decrease of
21.60%; RMB199 million were from anti-infection products, representing a YoY decrease of 43.29%;and
RMB122 million were from psychiatry products, representing a YoY decrease of 8.25%. APIs and
intermediates products realized revenues of RMB1,454 million, representing a YoY increase of 3.44%.
Traditional Chinese Medicine products realized revenues of RMB567 million, representing a YoY increase of
100.68%. Biological products realized revenues of RMB62 million, representing a YoY increase of 12.22%.
Diagnostic reagents and equipment products realized revenues of RMB147 million from, representing a YoY
decrease of 9.54%. Health care products realized revenues of RMB40 million, representing a YoY increase of
46.99%.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
Item For the Explanation
Reporting Period
Government grants recognized in profit or loss for the current
period (excluding government grants closely related to the Government gr
查看PDF原文
